FOLFOXIRI (IRINOTECAN, OXALIPLATIN, INFUSIONAL 5FU/LV) VS FOLFIRI AS FIRST-LINE TREATMENT OF METASTATIC COLORECTAL CANCER (MCRC): UPDATED RESULTS AFTER 5 YEARS FOLLOW UP AND RISK-STRATIFIED ANALYSIS

被引：0

作者：

Masi, G. ^{[1
]}

Vasile, E. ^{[1
]}

Loupakis, F. ^{[1
]}

Cupini, S. ^{[2
]}

Fornaro, L. ^{[1
]}

Baldi, G. ^{[2
]}

Salvatore, L. ^{[1
]}

Stasi, I ^{[1
]}

Brunetti, I ^{[3
]}

Ricci, S. ^{[3
]}

Palazzo, A. ^{[4
]}

Pellegrino, A. ^{[4
]}

Truscelli, K. ^{[4
]}

Garrone, M. ^{[5
]}

Chiara, S. ^{[6
]}

Ribecco, A. ^{[7
]}

Crino, L. ^{[8
]}

Andreuccetti, M. ^{[1
]}

Falcone, A. ^{[1
,2
]}

机构：

[1] Ist Toscano Tumori, Azienda Osped Univ Pisana, UO Oncol Med Univ 2, Pisa, Italy

[2] Ist Toscano Tumori, UO Oncol Med, Azienda USL Livorno 6, Livorno, Italy

[3] Ist Toscano Tumori, UO Oncol Med 1, Azienda Osped Univ Pisana, Pisa, Italy

[4] Univ Roma La Sapienza, UO Oncol B, Dipartimento Med Sperimentale, Rome, Italy

[5] Osped S Croce Carle, UO Oncol Med, Cuneo, Italy

[6] Ist Nazl Tumori, UO Oncol Med, Genoa, Italy

[7] Ist Toscano Tumori, Azienda Sanit Firenze, SC Oncol Med, Florence, Italy

[8] Osped S Andrea delle Fratte, UO Oncol Med, Perugia, Italy

来源：

ANNALS OF ONCOLOGY | 2009年 / 20卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页数：1

共 50 条

[1] FOLFOXIRI (irinotecan, oxaliplatin, infusional 5FU/LV) vs FOLFIRI as first-line treatment of metastatic colorectal cancer (mCRC): updated results after 5 years follow up and risk-stratified analysis
Falcone, A.
Masi, G.
Vasile, E.
Loupakis, F.
Cupini, S.
Mancini, M.
Granetto, C.
Ribecco, A.
Andreuccetti, M.
Brunetti, I. M.
EJC SUPPLEMENTS, 2009, 7 (02): : 348 - 348
[2] FOLFOXIRI (IRINOTECAN, OXALIPLATIN, INFUSIONAL 5FU/LV) VS FOLFIRI AS FIRST-LINE TREATMENT OF METASTATIC COLORECTAL CANCER (MCRC): UPDATED RESULTS AFTER 5 YEARS FOLLOW UP AND RISK-STRATIFIED ANALYSIS
Falcone, A.
Vasile, E.
Loupakis, F.
Cupini, S.
Baldi, G.
Fornaro, L.
Stasi, I
Salvatore, L.
Brunetti, I
Fabbri, M.
Chiara, S.
Granetto, C.
Ribecco, A.
Andreuccetti, M.
Masi, G.
ANNALS OF ONCOLOGY, 2009, 20 : 21 - 21
[3] The triplet combination of irinotecan, oxaliplatin and 5FU/LV (FOLFOXIRI) vs the doublet of irinotecan and 5FU/LV (FOLFIRI) as first-line treatment of metastatic colorectal cancer (MCRC): Results of a randomized phase III trial by the Gruppo Oncologico Nord Ovest (GONO).
Falcone, A.
Masi, G.
Brunetti, I.
Benedetti, G.
Bertetto, O.
Picone, V.
Chiara, S.
Merlano, M.
Vitello, S.
Ricci, S.
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 149S - 149S
[4] FOLFOXIRI (irinotecan, oxaliplatin, and infusional 5FU/LV) in combination with bevacizumab (BV) in the first-line treatment of metastatic colorectal cancer (mCRC): A phase II study by the GONO group
Falcone, A.
Masi, G.
Loupakis, F.
Vasile, E.
Ciarlo, A.
Cavaciocchi, D.
Amoroso, D.
Puglisi, M.
Fea, E.
Brunetti, I.
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[5] BEVACIZUMAB (BV) IN COMBINATION WITH FOLFOXIRI (IRINOTECAN, OXALIPLATIN AND INFUSIONAL 5FU/LV) AS FIRST-LINE TREATMENT OF METASTATIC COLORECTAL CANCER (mCRC): A PHASE II TRIAL BY THE GONO GROUP
Masi, G.
Vasile, E.
Loupakis, F.
Salvatore, L.
Fornaro, L.
Baldi, G.
Stasi, I
Cupini, S.
Ciarlo, A.
Del Monte, F.
Trenta, P.
Mezi, S.
Rondini, M.
Andreuccetti, M.
Falcone, A.
ANNALS OF ONCOLOGY, 2009, 20 : 12 - 12
[6] PHASE II STUDY OF FIRST-LINE TREATMENT IN METASTATIC COLORECTAL CANCER (MCRC) WITH GONO-FOLFOXIRI (IRINOTECAN, OXALIPLATIN AND INFUSIONAL 5FU/LV) PLUS BEVACIZUMAB (BV)
Masi, G.
Loupakis, F.
Vasile, E.
Ciarlo, A.
Cavaciocchi, D.
Ciprotti, M.
Donati, S.
Fea, E.
Di Donato, S.
Falcone, A.
ANNALS OF ONCOLOGY, 2008, 19 : 136 - 137
[7] First-line treatment of metastatic colorectal cancer (MCRC) with FOLFOXIRI (irinotecan, oxaliplatin and infusional 5FU/LV) in combination with bevacizumab (BV): A phase II study by the GONO group
Masi, G.
Loupakis, F.
Baldi, G.
Fornaro, L.
Stasi, I
Vasile, E.
Cialo, A.
Cavaciocchi, D.
Di Leo, A.
Puglisi, M.
Ciprotti, M.
Amoroso, D.
Fea, E.
Di Donato, S.
Falcone, A.
ANNALS OF ONCOLOGY, 2008, 19 : 26 - 26
[8] BEVACIZUMAB (BV) IN COMBINATION WITH FOLFOXIRI (IRINOTECAN, OXALIPLATIN AND INFUSIONAL 5FU/LV) IN METASTATIC COLORECTAL CANCER (MCRC): UPDATED RESULTS OF A PHASE II GONO TRIAL
Vasile, Enrico
Masi, Gianluca
Loupakis, Fotios
Salvatore, Lisa
Fornaro, Lorenzo
Cupini, Samanta
Di Marsico, Roberta
Antonuzzo, Andrea
Baldi, Giacomo Giulio
Stasi, Irene
Pfanner, Elisabetta
Ciarlo, Andrea
Del Monte, Francesca
Conte, Davide
Iacovelli, Roberto
Sonaglio, Claudia
Granetto, Cristina
Donati, Sara
Andreuccetti, Michele
Falcone, Alfredo
ANNALS OF ONCOLOGY, 2009, 20
[9] Bevacizumab (BV) in combination with FOLFOXIRI (irinotecan, oxaliplatin and infusional 5FU/LV) in metastatic colorectal cancer (MCRC): updated results of a phase II GONO trial
Masi, G.
Salvatore, L.
Fornaro, L.
Vasile, E.
Baldi, G. G.
Stasi, I.
Ciarlo, A.
Tuzi, A.
Andreuccetti, M.
Falcone, A.
EJC SUPPLEMENTS, 2009, 7 (02): : 346 - 346
[10] Biweekly irinotecan, oxaliplatin and infusional 5FU/LV (FOLFOXIRI) versus folfiri as first-line treatment of metastatic colorectal cancer (MCRC):: Results of a randomized phase III trial by the gruppo oncologico nord ovest (GONO)
Masi, G.
Allegrini, G.
Brunetti, I.
Murr, R.
Ricci, S.
Benedetti, G.
Crino, L.
Fanchini, L.
Bertetto, O.
Picone, V.
Cortesi, E.
Vitello, S.
Chiara, S.
Rosso, R.
Granetto, C.
Merlano, M.
Porcile, G.
Alabisio, O.
Fioretto, L.
Falcone, A.
ANNALS OF ONCOLOGY, 2005, 16 : 7 - 7

← 1 2 3 4 5 →